240 related articles for article (PubMed ID: 36915038)
1. A novel cuproptosis-related gene signature to predict prognosis in Glioma.
Zhang M; Liu X; Wang D; Ruan X; Wang P; Liu L; Xue Y
BMC Cancer; 2023 Mar; 23(1):237. PubMed ID: 36915038
[TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
4. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
6. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
[TBL] [Abstract][Full Text] [Related]
7. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
8. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
Front Genet; 2022; 13():992995. PubMed ID: 36579333
[No Abstract] [Full Text] [Related]
9. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
10. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
12. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
[TBL] [Abstract][Full Text] [Related]
13. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
14. Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma.
Chen S; Zhang S; Yuan Y; Wang Z; Li J; Li T; Zuo M; Feng W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1016520. PubMed ID: 36267281
[TBL] [Abstract][Full Text] [Related]
15. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma.
Ye Z; Zhang S; Cai J; Ye L; Gao L; Wang Y; Tong S; Sun Q; Wu Y; Xiong X; Chen Q
Front Oncol; 2022; 12():967159. PubMed ID: 36059638
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
[TBL] [Abstract][Full Text] [Related]
18. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
20. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
